ART714 is a best-in-class antileukemic 2-carbon-linked dimeric artemisinin derivative.

MLA

Kagan, Amanda B., et al. “ART714 Is a Best-in-Class Antileukemic 2-Carbon-Linked Dimeric Artemisinin Derivative.” Cancer Chemotherapy and Pharmacology, vol. 92, no. 1, July 2023, pp. 39–50. EBSCOhost, https://doi.org/10.1007/s00280-023-04539-2.

APA

Kagan, A. B., Moses, B. S., Lapidus, R., Mott, B. T., Rai, G., Anders, N. M., Hoag, S. W., Rudek, M. A., & Civin, C. I. (2023). ART714 is a best-in-class antileukemic 2-carbon-linked dimeric artemisinin derivative. Cancer Chemotherapy and Pharmacology, 92(1), 39–50. https://doi.org/10.1007/s00280-023-04539-2

Chicago

Kagan, Amanda B, Blake S Moses, Rena Lapidus, Bryan T Mott, Ganesha Rai, Nicole M Anders, Stephen W Hoag, Michelle A Rudek, and Curt I Civin. 2023. “ART714 Is a Best-in-Class Antileukemic 2-Carbon-Linked Dimeric Artemisinin Derivative.” Cancer Chemotherapy and Pharmacology 92 (1): 39–50. doi:10.1007/s00280-023-04539-2.